ethyl 4-(4-((1,1,1-trifluoro-2-methylpropan-2-yl)carbamoyl)piperidin-1-yl)azepane-1-carboxylate | 1438242-32-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: ethyl 4-(4-((1,1,1-trifluoro-2-methylpropan-2-yl)carbamoyl)piperidin-1-yl)azepane-1-carboxylate
• 英文别名: Ethyl 4-[4-[(1,1,1-trifluoro-2-methylpropan-2-yl)carbamoyl]piperidin-1-yl]azepane-1-carboxylate
• CAS: 1438242-32-0
• 化学式: C₁₉H₃₂F₃N₃O₃
• 分子量: 407.477
• InChiKey: FSGQJOYYOQGRIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] MUSCARINIC M1 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2013072705A1

  公开（公告）日：2013-05-23

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.

  这项发明涉及激动毒蕈碱M1受体的化合物，这些化合物在治疗毒蕈碱M1受体介导的疾病中很有用。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。提供的化合物符合式I，其中n为1或2；p为0、1或2；q为0、1或2；R1-R6如本文所定义。
• MUSCARINIC M1 RECEPTOR AGONISTS
  申请人：HEPTARES THERAPEUTICS LIMITED

  公开号：US20140329803A1

  公开（公告）日：2014-11-06

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R 1 -R 6 are as defined herein.

  本发明涉及一种肌动蛋白M1受体激动剂化合物，可用于治疗肌动蛋白M1受体介导的疾病。同时还提供了含有该化合物的药物组合物以及该化合物的治疗用途。所提供的化合物为公式I，其中n为1或2；p为0、1或2；q为0、1或2；R1-R6如本文所定义。
• Muscarinic M1 Receptor Agonists
  申请人：Heptares Therapeutics Limited

  公开号：US20160068508A1

  公开（公告）日：2016-03-10

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R 1 -R 6 are as defined herein.

  本发明涉及肌动蛋白M1受体的激动剂化合物，用于治疗肌动蛋白M1受体介导的疾病。还提供了含有该化合物的制药组合物和该化合物的治疗用途。所提供的化合物为公式I，其中n为1或2；p为0、1或2；q为0、1或2；R1-R6如本文所定义。
• Muscarinic M1 receptor agonists
  申请人：Heptares Therapeutics Limited

  公开号：US10413553B2

  公开（公告）日：2019-09-17

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体的激动剂，可用于治疗毒蕈碱 M1 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。所提供的化合物为式I，其中n为1或2；p为0、1或2；q为0、1或2；R1-R6如本文所定义。
• US9187451B2
  申请人：——

  公开号：US9187451B2

  公开（公告）日：2015-11-17